Isothiocyanates inhibit proteasome activity and proliferation of multiple myeloma cells

Lixin Mi1, Nanqin Gan, Fung-Lung Chung

  • 1Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20057, USA. lm293@georgetown.edu

Carcinogenesis
|November 27, 2010
PubMed

Insights

Benzyl isothiocyanate (BITC) and phenethyl isothiocyanate (PEITC) inhibit proteasome activity, leading to cancer cell death. These compounds suppress multiple myeloma growth by inducing cell cycle arrest and apoptosis.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Cancer Research

Background:

  • Isothiocyanates (ITCs) from cruciferous vegetables induce cancer cell apoptosis.
  • Previous research suggested reactive oxygen species (ROS) mediate ITC-induced apoptosis.
  • Our recent findings highlight covalent protein binding as a key event in apoptosis induction.

Purpose of the Study:

  • To investigate the effect of ITCs on proteasome activity.
  • To determine the mechanism of ITC-induced proteasome inhibition.
  • To evaluate the efficacy of ITCs in suppressing multiple myeloma (MM) cell growth.

Main Methods:

  • Assessing proteasome activity in various cell types after ITC treatment.
  • Investigating the direct binding of ITCs to 20S and 26S proteasomes.
  • Analyzing the accumulation of p53 and nuclear factor-kappaB (NF-κB) inhibitor IκB.
  • Evaluating the impact of BITC and PEITC on MM cell proliferation, cell cycle, and apoptosis.

Main Results:

  • BITC and PEITC significantly inhibit both 20S and 26S proteasome activity.
  • Proteasome inhibition by ITCs is independent of ROS generation or protein aggregation.
  • Inhibition potency correlates with p53 and IκB accumulation.
  • BITC and PEITC suppress MM cell growth via G₂/M cell cycle arrest and apoptosis.

Conclusions:

  • Proteasome is a potential molecular target of ITCs, similar to tubulin.
  • This study reveals a novel mechanism for ITC-mediated inhibition of MM cell growth.
  • ITCs show promise as therapeutic and preventive agents for MM.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
The Proteasome02:18

The Proteasome

Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
The Proteasome01:13

The Proteasome

Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3 (ubiquitin...